<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Introduction: The use of rituximab has led to significant improvements in the outcome of both aggressive and indolent Non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) </plain></SENT>
<SENT sid="1" pm="."><plain>It is the first targeted therapy to be developed for the treatment of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> which has been widely adopted </plain></SENT>
<SENT sid="2" pm="."><plain>Areas covered: This paper discusses the use of rituximab in NHL, mainly concentrating on diffuse large B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL), with a brief discussion about use in other types of NHL including mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>The use of rituximab in <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL) has been recently published in this journal by Robak (Robak T </plain></SENT>
<SENT sid="4" pm="."><plain>Rituximab for <z:hpo ids='HP_0005550'>chronic lymphocytic Leukemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Expert Opin Biol </plain></SENT>
<SENT sid="6" pm="."><plain>Ther </plain></SENT>
<SENT sid="7" pm="."><plain>2012;12(4):503-15) </plain></SENT>
<SENT sid="8" pm="."><plain>Non hematological indications for rituximab are also not discussed </plain></SENT>
<SENT sid="9" pm="."><plain>A Pubmed search was conducted using key words of rituximab, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, FL, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>, Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and MALToma </plain></SENT>
<SENT sid="10" pm="."><plain>Papers shortlisted for review included randomized control trials and scientific papers discussing CD20 </plain></SENT>
<SENT sid="11" pm="."><plain>Expert opinion: In conclusion this paper has critically evaluated the use of rituximab in the treatment mainly of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, FL and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> both at diagnosis and <z:e sem="disease" ids="C0277556" disease_type="Disease or Syndrome" abbrv="">relapsed disease</z:e>, and briefly discuses its use in other subtypes of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Rituximab has significantly improved the outcome of patients with B cell NHL, in particular those with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and FL </plain></SENT>
<SENT sid="13" pm="."><plain>Patients usually tolerate the treatment well, and studies have shown it to be a cost effective treatment </plain></SENT>
</text></document>